Anti-human P40 protein domain antibody and use thereof

An antibody or an antigen-binding fragment thereof, wherein the antibody comprises:

• (1) a heavy chain variable region comprising or consisting of:
• an amino acid sequence set forth in SEQ ID NO:
• 1, or
• a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:
• 1, and comprising HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, and
• a light chain variable region comprising or consisting of:
• an amino acid sequence set forth in SEQ ID NO:
• 6, or
• a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:
• 6 and comprising LCDR1 of SEQ ID NO:8, LCDR2 of SEQ ID NO:9 and LCDR3 of SEQ ID NO:10,
• (2) a heavy chain variable region comprising or consisting of:
• an amino acid sequence set forth in SEQ ID NO:
• 1, or
• a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:
• 1 and comprising HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5;
• and
• a light chain variable region comprising or consisting of:
• an amino acid sequence set forth in SEQ ID NO:
• 11, or
• a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:
• 11 and comprising LCDR1 of SEQ ID NO:19, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:22,
• (3) a heavy chain variable region comprising or consisting of:
• an amino acid sequence set forth in SEQ ID NO:
• 1, or
• a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:
• 1 and comprising HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5;
• and
• a light chain variable region comprising or consisting of:
• an amino acid sequence set forth in SEQ ID NO:
• 15, or
• a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:
• 15 and comprising LCDR1 of SEQ ID NO:20, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:22,
• (4) a heavy chain variable region comprising or consisting of:
• an amino acid sequence set forth in SEQ ID NO:
• 1, or
• a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:
• 1 and comprising HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5;
• and
• a light chain variable region comprising or consisting of:
• an amino acid sequence set forth in SEQ ID NO:
• 17, or
• a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:
• 17 and comprising LCDR1 of SEQ ID NO:20, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:23, or
• (5) a heavy chain variable region comprising or consisting of:
• an amino acid sequence set forth in SEQ ID NO:
• 24, or
• a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:
• 24 and comprising HCDR1 of SEQ ID NO:26, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5;
• and
• a light chain variable region comprising or consisting of:
• an amino acid sequence set forth in SEQ ID NO:
• 25, or
• a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:
• 25 and comprising LCDR1 of SEQ ID NO:27, LCDR2 of SEQ ID NO:28 and LCDR3 of SEQ ID NO:22,
• wherein the antigen-binding fragment is selected from the group consisting of:
• Fab, Fab′, F(ab′)2, Fv, Fab/c, single chain antibody, and bivalent antibody.